bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand name including Biktarvy. Available dosage form: tablet.
Drug details
- Generic Name
- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
- Brand Names
- Biktarvy
- Application Number
- NDA210251
- Sponsor
- A-S Medication Solutions
- NDC Codes
- 12
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- BICTEGRAVIR SODIUM, EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE
Indications and Usage
1 INDICATIONS AND USAGE BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. BIKTARVY is a three-drug combination of bictegravir (BIC), a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. ( 1 )